Article

Real-world antipsychotic treatment practices

University of Texas at San Antonio, San Antonio, Texas, United States
The Psychiatric clinics of North America (Impact Factor: 1.87). 10/2007; 30(3):401-16. DOI: 10.1016/j.psc.2007.04.008
Source: PubMed

ABSTRACT This article examines real-world antipsychotic use in the treatment of schizophrenia by comparing real-world prescribing with medication algorithms and guidelines, by evaluating the evidence underlying recommendations and guidelines, and by examining the roles of side effects and medication adherence in real-world prescribing decisions.

1 Bookmark
 · 
178 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic symptoms induced by antipsychotic medication have been widely documented but there have been few studies comparing the effect of commonly used atypical antipsychotics on blood glucose and lipids among individuals with first-onset schizophrenia. A total of 150 patients with first-onset schizophrenia were randomized into three groups and each group was treated with olanzapine, quetiapine, or aripiprazole for eight weeks. Blood glucose and lipids (including levels of triglyceride, total cholesterol, low-density lipoprotein, and high-density lipoprotein) were tested at baseline and at the end of the 8 weeks of treatment. Fasting blood glucose increased significantly over the 8 weeks in the olanzapine group but not in the quetiapine or aripiprazole groups. Based on a repeated measures analysis of variance, triglyceride levels increased significantly over the 8 weeks of treatment and high-density lipoprotein decreased significantly over the 8 weeks of treatment. The increase in triglyceride in the olanzapine and quetiapine groups was greater than that in the aripiprazole group, and the decrease in high-density lipoprotein was greater in the olanzapine and quetiapine groups than in the aripiprazole groups. During the first 8 weeks of treatment of drug-naïve patients with schizophrenia, olanzapine has a greater effect on blood glucose than quetiapine or aripiprazole, and both olanzapine and quetiapine have a greater effect on blood lipids than aripiprazole.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.
    01/2014; 2014:904829. DOI:10.1155/2014/904829
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is the report of a case of a patient who presented her first psychotic episode at the age of 48 years old with a predominance of delusional symptoms but with a torpid and severe family and social dysfunction meriting psychiatric hospitalization for 83 days because of her difficult treatment and a considerable multiple pharmacological schemes that interfere on the diagnosis and prognosis; the importance of the approach and the differential diagnosis that has to be taken into account to the variety of psychotic symptoms that are part of the diagnosis of schizophrenia, but they certainly are not pathognomonic of it.
    Salud Mental 04/2011; 34(2):175-179. · 0.42 Impact Factor

Full-text

Download
13 Downloads
Available from
Dec 26, 2014